Science & Health
Medical Marijuana Patients Are Turning To Lesser-Known Cannabinoids Like CBG And CBN, Analysis Of Reddit Posts Shows (Op-Ed)
“The minor cannabinoids that receive far less attention in the mainstream market are often the same compounds patients repeatedly describe as helpful.”
By Sunehera Hasib
The cannabis industry spends millions pushing specific products. But patients are having a very different conversation among themselves.
In a recent analysis of nearly 18,000 posts and comments across major cannabis and medical marijuana communities on Reddit, an unfiltered picture of patient-led experimentation emerges. Unlike a clinical trial or industry survey, these were everyday conversations between people trying to figure out what works for them. And what emerged was a striking landcape of patients experimenting beyond the cannabinoids that dominate dispensary shelves and marketing campaigns.
In some cases, the compounds receiving the least attention were the ones patients repeatedly mentioned when describing relief.
To capture these patterns, I compiled posts from the subreddits r/MMJ, r/hempflowers, r/trees, r/MedicalMarijuana, r/marijuana, r/MedicalCannabis_NI and r/CBD. Of the posts noting a clear outcome, 84.6 percent described positive results.
These self-reported experiences cannot replace clinical trials or prove medical efficacy, but they do reveal something vital. They give us a direct look at patient behavior, showing what people are experimenting with at home and which cannabinoids consistently earn a mention when patients talk about real-life relief.
It is worth saying up front that this is self-reported, unverified and not something anyone should read as a clinical finding.
Minor Cannabinoids Are The Focus Of Some Of The The Highest Rates Of Positive Experiences
THC and CBD together still dominate the conversation; they’re mentioned far more often than CBG, CBN or CBC combined. But among patients who said whether a cannabinoid worked for them, CBG and CBN show up with some of the highest shares of positive reports in the dataset, particularly around pain, inflammation and sleep.
- CBG, posts about inflammation: 40 of 40 outcome-reporting posts described a positive experience.
- CBG, posts about pain: 97.1 percent of firsthand reports were positive (67 of 69)
- CBN, posts about sleep: 95.3 percent positive (122 of 128 firsthand reports)
- CBG, posts about anxiety: 90.1 percent positive firsthand (73 of 81)
For comparison, CBD alone for pain came in at 94.4 percent positive and THC alone at 90.1 percent, both strong numbers in their own right. CBG’s share was a bit higher, though the sample sizes for CBG are smaller, and this isn’t a controlled comparison of any kind, so it’s more of a pattern worth watching than a verdict.
Patients Are Working Things Out For Themselves
What stood out most was how detailed these posts got. Instead of a one-line “it helped,” people described actual routines: stacking CBG in the morning with CBD in the evening and CBN before bed, choosing CBG because they felt it didn’t carry the sedation some associate with high-dose CBD, using CBG topically alongside THC during flares.
Whether or not that reflects anything pharmacological, it’s the kind of granular, self-taught trial-and-error that hasn’t shown up much in mainstream product marketing yet.
Terpenes Are Also A Focus Of Conversation
Terpenes are mentioned far less often than cannabinoids in casual posts, so these patterns are more suggestive than conclusive. Patients frequently associated myrcene with muscle relaxation and pain relief, caryophyllene with reduced inflammation and limonene with improved mood. Posts naming those terpenes skewed positive.
Pinene stood out, though for less reassuring reasons.
In 29 posts specifically discussing anxiety, pinene skewed noticeably negative compared to other terpenes, with firsthand reports highlighting heightened anxiety rather than relief. A couple of patients noted this pattern themselves: one mentioned avoiding sativa strains because of their pinene content, pointing to it as a trigger for worsened PTSD symptoms; another described pinene as energizing but warned that “for you it might be anxiety.”
With a sample this small, it is not something to draw a firm conclusion from, but it is a distinct enough pattern that it seemed worth flagging.
Anxiety Is The Most-Discussed Condition, But Results Are The Least Consistent
Anxiety was the single most-discussed condition in the dataset, and it’s also where results looked the most mixed: CBD-heavy anxiety posts ran 88.1 percent positive firsthand, while THC-heavy posts dropped to 58.1 percent, with a real cluster of reports describing heightened panic or paranoia instead of relief.
That doesn’t mean cannabis “doesn’t work” for anxiety. It may say more about cannabinoid choice, and possibly delivery method, mattering more for anxiety than they seem to for pain or sleep. Several people described switching from smoking to CBD-only or low-THC formats after noticing their own reactions, through their own trial and error rather than any guidance.
This contrast also raises questions about how cannabinoid dose and individual differences in the endocannabinoid system may influence responses to THC. Without accessible guidance on cannabinoid dosing, product selection and individual responses, many people appear to be navigating these threshold effects largely through trial and error.
Patients are essentially running a massive, decentralized process of personalized experimentation on their own. They test products, track outcomes and share insights publicly without relying on brand marketing or formal medical guidance.
Structuring this organic community data will never replace clinical research, but it points to a gap the industry should acknowledge: the minor cannabinoids that receive far less attention in the mainstream market are often the same compounds patients repeatedly describe as helpful.
Finally, a note about methodology: This analysis used keyword and pattern-based sentiment classification across publicly available Reddit posts. With any large-scale natural language processing workflow, minor classification noise or misassigned edge cases can occur. However, the overarching patterns across these 17,789 posts remain remarkably consistent, and these findings are hypothesis-generating and could help identify questions for future clinical research. The full dataset filtered by symptom and cannabinoid is available on my interactive dashboard.
Sunehera Hasib is a data scientist and public health researcher with interests in behavioral health, clinical research and digital health. Her work focuses on using health data to better understand patient experiences, identify unmet needs and translate research into practical insights.
